1. Home
  2. Investments
  3. Oda Group

Norway’s leading online grocery retail platform

Oda at a glance

Oda is Norway’s leading online grocery retail platform, offering a wide range of fresh and dry food, and household products at competitive prices with home delivery to its >80k Norwegian customers. Oda’s mission is to be the most efficient and sustainable online grocer in the world, leveraging its best-in-class operational efficiency and its already superior food waste reduction compared to traditional grocery retailers.

Revenue
EUR 476m
Location
Norway
Employees
2394
Investment theme
Sustainable Food
SDG alignment

12, 13

The challenges we face:

  • 2-5%

    global average spoilage share of ­operating revenues for online grocery retailers
  • 1.5Kg

    of CO2e emissions per order from store to home ­transportation in Norway in 2021

How does Oda Group help?

  • Reality today

    Our food value chain is inefficient, with unnecessary food waste, significant transportation emissions, and unsustainable customer food choices.

  • Oda approach

    Oda improves responsible consumption and production within our food system – mainly driven by operational efficiencies in its supply chain. Food waste emissions are approx. 50% lower compared to traditional grocery retailers and transportation emissions are reduced by 13% by optimizing fuel consumption and utilizing electric transport and eliminating consumer trips to and from grocery stores.

  • Aspirational future

    A less wasteful and emission-intensive food system where food waste is reduced and consumers are empowered to choose healthier products.

  • Who is impacted?

    Consumers in Norway and Sweden can access products from a more efficient supply chain, providing lower emissions associated with their purchases. The wider society and environment is indirectly impacted through reduced emissions and food waste.

  • Contribution

    Oda actively minimizes food waste within its retail operations and achieves lower emissions through optimized transport, demonstrating a tangible impact on the food value chain. This operational efficiency further allows them to provide consumers with access to sustainable product choices.

  • Risks to impact

    While Oda works to minimize own spoilage share and last-mile delivery emissions, its limited control over upstream factors (e.g. supplier practices affecting shelf life) and downstream customer behavior (order frequency and last-mile efficiency) could pose risks to maintaining levels of impact.

KPI reporting

Average last mile delivery emissions per order (kg CO2e)

Target 2027: 0.6

Change from '23-'24: -29%

2024
1
2023
1
2022
1

Average last mile refers to the emissions associated with the final transportation leg, i.e.: delivering the order to the customer.

Spoilage share of operating revenue (%)

Target 2027: 0.2%

Change from '23-'24: 0.09ppt

2024
1%
2023
1%
2022
1%

Spoilage share is the amount of food spoiled (including food donated or sold by a third party) as a share of operating revenue.

Average climate footprint of food ­ products (kg CO2e/kg)

Change from '22-'23: 0%

2024
2
2023
2
2022
2

Average climate footprint of food products is the emissions associated with the production and distribution of a food product.

  1. Home
  2. Investments
  3. Sengenics

Immunoprofiling for advanced biomarker discovery

Sengenics at a glance

Sengenics is a one-of-a-kind immune­proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded, and functional proteins. The technology is used to support pharma and academic research to advance precision medicine through an increased understanding of the autoimmune response in humans. Sengenics is currently focused on measurement of auto­antibodies for applications in autoimmune diseases, oncology, neurological conditions, and infectious disease.

Year acquired
2020
Employees
45
Investment theme
Changing Demographics
SDG alignments
3

What are the challenges Sengenics addresses

  • 80%

    of patients receive no benefit from treatment with the top 10 best-selling drugs in the world
  • 9.2%

    of OECD GDP is spent on healthcare

How does Sengencis help?

Reality today

We do not understand the biology of many leading diseases and lack appropriate biomarkers, preventing us from developing effective medication and delivering precision treatment.

Sengencis approach

Sengenics proteomics technology enables biological response research at unrivalled sensitivity and specificity, helping develop more targeted, effective, and efficient diagnostics and therapies.

Aspirational future

Deeper understanding of human biology and disease allows us to develop and deliver the most effective diagnostics and treatments for patients.

Who is impacted?

Researchers are impacted directly through more effective tools to understand human biology and more effective drug development. Patients are impacted indirectly through breakthroughs in treatments.

Contribution

Sengenics unique technology and collaborative partnerships with top biopharma companies contributes to the advancement of research on how to develop more targeted, effective and efficient diagnostics and therapies.

Risks

Sengenics impact depends in part on how its customers in biopharma choose to use its tools. Product quality is also fundamentally important, enabling reproducibility in research and precise, safe innovation in therapies.

KPI reporting

Accumulated no. of publications

Change from '22-'23: 28%

2023
51
2022
40
2021
31

Accumulated no. of publications measures the total publications produced using Sengenic’s technology and thereby contributing to precision medicine.

Data points generated

Change from '22-'23: 117%

2023
26m
2022
12m
2021
9m

Data points generated measures the total count of individual pieces of data on proteins or autoantibodies generated within a year.

Number of samples profiled

Change from '22-'23: -5%

2023
4,611
2022
4,833
2021
4,090

Number of samples profiled quantifies the total count of biological samples analyzed or characterized within a year.

  1. Home
  2. Investments
  3. LOGEX

Turning data into better healthcare

LOGEX at a glance

LOGEX is the European leader in advanced analytics for healthcare, serving providers, payors, and authorities. The company has the most comprehensive product portfolio in its field in Europe and the broadest geographical reach. LOGEX has three main business units: Financial Analytics (e.g., cost, resource allocation, planning), Outcomes Analytics (e.g., healthcare quality outcome measurement and bench marking), and Life Sciences (real world evidence data and analytics).

Year acquired
2018
Revenue
EUR 59.2m
Location
Europe
Employees
415
Investment theme
Changing Demographics
SDG alignment

3, 9

What are the challenges LOGEX addresses

  • 9.2%

    of OECD GDP is spent on healthcare
  • 10m

    shortage of health workers projected globally by 2030

How does LOGEX help?

  • Reality today

    The ever-increasing need for quality and consistent patient care and improved outcomes is significantly impacted by the rising costs that healthcare systems must address.

  • LOGEX approach

    LOGEX’s software solutions and analytical tools provide unprecedented insight into care delivery, cost, and patient outcomes, enabling more quality-centric, cost-conscious approaches to healthcare and pharma.

  • Aspirational future

    Patients consistently receiving care that is affordable, meets their needs, and passes the highest standards of quality.

  • Who is impacted?

    Patients are impacted by the quality and affordability of care. Healthcare systems, including providers and payors, are impacted by the cost and efficiency of care delivery.

  • Contribution

    LOGEX’s growing suite of solutions contributes to accelerating the transition to more cost-effective, patient-centric, and integrated care – enabling players in the healthcare system to deliver optimal patient outcomes.

  • Risks to impact

    LOGEX works to maintain the highest data privacy and security standards, including meeting internationally recognized certifications, in order to mitigate risks posed by handling healthcare and patient data. The company’s impact also depends on the pace of transformation towards value-based care. LOGEX is working to help drive an inflection point for more rapid change.

KPI reporting

Healthcare institutions using LOGEX tools

Target 2026: 1,500

Change from '23-'24: -16%

2024
895
2023
0N/A
2022
0N/A

Healthcare institutions using LOGEX tools indicates how many institutions leverage them to optimize operations, improve efficiency, and enhance overall performance.

Impact stories captured

Target 2026: 80

Change from '23-'24: +33%

2024
40
2023
30
2022
20

Impact stories captured refers to turning data into useful insights that help decision ­ makers and healthcare professionals optimize treatment.

  1. Home
  2. Investments
  3. G-CON Manufacturing

Cleanroom Solutions for Advanced Technology Industries

G-CON at a glance

G-CON innovates and delivers unrivalled cleanroom solutions for advanced technology industries with speed, certainty, and sustainability. G-CON designs, builds, and installs pre­fabricated cleanrooms PODs for pharma biotech companies providing a fully functional clean room that is easy to install, has a lower total cost of ownership, faster delivery times, and more consistent quality. G-CON acquired Plasteurop to further its footprint into the site-installed clean components market, providing components for the life science, semi-conductor, and battery market, expanding our offering and market opportunities.

Year acquired
2021
Revenue
EUR 45m
Location
United States
Employees
247
Investment theme
Changing Demographics
SDG alignment

3, 9

What are the challenges G-CON addresses

  • 3x

    the current semiconductor capacity is projected to be achieved by 2032
  • ~ 1-3

    years average time from project conception to drug availability on the market

How does G-CON help?

  • Reality today

    Cleanroom construction for advanced technology is complicated, and the process of designing, sourcing and building a facility is complex and inefficient, resulting in unreliable delivery schedules and budgets.

  • G-CON approach

    G-CON’s portfolio of modular and PODular solutions reduces variability and lead times, while providing the highest quality and certainty of cost and schedule for facility projects.

  • Aspirational future

    The rapid and reliable deployment of manufacturing capability in advanced technology industries through industry adoption of prefabricated facility solutions that are responsibly produced, efficient in operation and have durable value that encourages re-use.

  • Who is impacted

    The rapid deployment of cleanroom facilities directly benefits advanced technology manufacturers, accelerating their critical operations. This ultimately leads to patients receiving drugs faster and society benefiting from quicker access to locally produced technologies like semiconductors.

  • Contribution

    G-CON’s innovative cleanroom solutions disrupt traditional lengthy and inefficient on-site construction approaches, contributing to the ability of critical industries to develop, manufacture, and distribute advanced technology products more rapidly.

  • Risks to impact

    G-CON’s impact on advanced technology manufacturing is dependent on two key drivers: 1: Increased adoption of prefabricated, and modular cleanroom solutions; and 2: Industry funding and investment in new facility infrastructure to support capacity requirements.

KPI Reporting

Total cleanroom space (sqm)

Target 2027: 100,000

Change from '23-'24: -60%

2024
21,300
2023
53,812
2022
8,000

Total cleanroom space (sqm) measures the total manufacturing area in square meters, ­ dedicated to cleanroom facilities within advanced­ technology industries.

Total recordable incident rate

Target 2027: 1.3

Change from '23-'24: -11%

2024
2
2023
3
2022
0N/A

Total recordable incident rate measures the frequency of workplace incidents resulting in injury, illness, or other recordable events per total number of hours worked.

  1. Home
  2. Investments
  3. Axion Biosystems

Instruments for customers in biopharma and academia

Axion at a glance

Axion Biosystems (“Axion”) is a global life science tools business headquartered in the US that develops, produces, and markets BEA (Bioelectronic Assay) and live-cell imaging instruments for customers in biopharma and academia. Axion’s products enable scientists to understand cell function in real-time, enabling research and the development of new therapies across various pharmaceutical segments (e.g., cell and gene therapies).

 

 

Year acquired
2021
Revenue
EUR 25.6m
Location
United States
Employees
142
Investment theme
Changing Demographics
SDG alignment

3, 9

What are the challenges Axion addresses

  • #1

    neurological conditions are the leading cause of ill health and disability worldwide and there are no treatments available to cure
  • 90%

    of drugs that pass through preclinical studies fail to meet the efficacy or safety margins required in subsequent trials

How does Axion help?

  • Reality today

    The live-cell perspective is not fully integrated in the development of therapies and scientists need better tools to understand cell function to target diseases and drive patient outcomes.

  • Axion approach

    Axion enables multi-dimensional, interoperable live-cell analysis to improve drug discovery and development without animal testing. Their products drive breakthroughs in cell and gene therapies across a wide spectrum of neurological research, ultimately leading to superior health outcomes.

  • Aspirational future

    Faster, more accurate and cost-efficient drug discovery and development for precision medicine through real-time understanding of cell functioning and enablement of cutting-edge fields within biotechnology and medicine that address various medical conditions such as cancer, genetic disorders, and autoimmune diseases.

  • Who is impacted?

    Researchers and biopharma are impacted directly by gaining insights through more effective tools that increase the understanding of cell functions. Patients are impacted indirectly through breakthroughs in treatment developments.

  • Contribution

    Axion enables academia and biopharma to gain insights into cell function, and thereby contributes to speeding up the time and increasing the quality of critical drug development.

  • Risks to impact

    Axion’s impact depends partly on how its customers in academia and biopharma choose to use its tools. Engaging with customers can help to ensure that the research and innovation it enables translates into patient outcomes downstream.

KPI reporting

Number of publications

Target 2027: 245

Change from '23-'24: +16%

2024
237
2023
204
2022
178

Number of publications measures the quantity of publications produced using Axion’s products, indicating contribution to research output on cell functioning.

Number of systems sold to Cell Gene Therapy (“CGT”) companies

Change from '23-'24: -48%

2024
14
2023
27
2022
22

Number of systems sold to CGT companies measures the enablement of companies operating in this cutting-edge field of biotechnology.

Number of experiments run

Target 2027: 1,045,000

Change from '23-'24: 0.2%

2024
851k
2023
853k
2022
790k

Number of experiments run quantifies the total count of scientific or research experiments­ conducted within a year, using Axion’s technology.

  1. Home
  2. Investments
  3. myneva

Software solutions provider for the social sector

myneva at a glance

The myneva Group is one of the leading European software providers for all areas of social services. With over 290 employees, more than 3,900 customers and serving around 1,500,000 clients with its software solutions in the social sector, myneva covers the entire social sector from care for the elderly, integration assistance, child, and youth welfare to social assistance. As the only software provider in this sector, myneva is currently active in eight European countries (Germany, Netherlands, Finland, Austria, Switzerland, United Kingdom, Luxembourg, Belgium)

Year acquired
2021
Revenue
EUR 53.7m
Location
Germany
Employees
368
Investment theme
Tech-Enabled Resilience
SDG alignment

3, 8, 10

What are the challenges myneva addresses

  • 70%

    increase in the share of EU GDP spent on long-term care between 2016 and 2070
  • 25-36%

    of a caregiver’s time is dedicated to administrative duties

How does myneva help?

  • Reality today

    A growing and aging global population is putting increasing pressure on care provision, with risks to quality and outcomes for long-term care, youth care, and disability care due to significant labor shortages.

  • myneva approach

    myneva’s mission is to support caregivers with first-class solutions and expertise that make their care work easier and simultaneously improve time spent by caregivers to the quality of life of those in need of care.

  • Aspirational future

    Long-term care is more effective, efficient, and accessible, with improved health and wellbeing for the elderly, disabled, and sick people.


  • Who is impacted?

    Patients are impacted through higher quality, better organized, digitized care where myneva’s software streamlines administrative processes and thus enables caregivers to spend more time per patient. Caregivers are also positively impacted through a more positive, better organized caregiving experience.

  • Contribution

    myneva’s software solutions support caregivers in their daily work and thereby contribute to shape and accelerate high-quality, efficient care delivery in Europe.

  • Risks to impact

    myneva works to minimize data security risks by using strict routines and protections for personal data. The impact of myneva’s solutions also depend on effective implementation and use from care organizations, which can be ensured by proper implementation and onboarding.

KPI reporting

Patients treated through myneva systems and solutions

Target 2030: 2,500,000

Change from '23-'24: 9%

2024
1,666,575
2023
1,526,000
2022
1,523,000

The number of patients benefiting from caregivers reduced time spent on admin.

Caregivers engaged through myneva systems and solutions

Target 2030: 839,000

Change from '23-'24: 19%

2024
537,633
2023
450,995
2022
439,000

The number of caregivers enabled to reduce time on admin.

Admin time saved by caregivers per day through myneva systems and solutions (hours)

Target 2030: 418,000

Change from '23-'24: 91%

2024
428,297
2023
223,998
2022
219,000

This KPI indicates the potential time spent conducting care instead of admin.

  1. Home
  2. Investments
  3. Infobric

We help build a better world

Infobric at a glance

Infobric is a construction software company with the purpose of enabling a safe, resource-efficient, and sustainable construction industry. The company offers end-to-end construction software for workforce-, contractor-, equipment- and asset-management. The company was founded in 2004 and has become the market leader in Sweden, Norway, and the UK by delivering high-quality solutions. Infobric has also started to build a presence in several other countries.

Year acquired
2019
Revenue
EUR 64.8m
Location
Sweden
Employees
292
Investment theme
Tech-Enabled Resilience
SDG alignment

8, 9, 16

What are the challenges Infobric addresses

  • > 20%

    of all fatal accidents at work in the EU occurs in the construction industry
  • 35%

    of the total waste generated in the EU comes from construction and demolition

How does Infobric help?

  • Reality today

    The construction industry is defined by high rates of workplace accidents, limited labor rights, and slow growth and low efficiency compared to other industries.

  • Infobric approach

    Infobric’s digital solutions radically improve the management of construction workers and equipment, helping reduce workplace accidents, fraud, and undocumented labor, while contributing to drive environmental impact for customers.

  • Aspirational future

    The construction industry is safe and supportive for workers, sustainable for the environment, and free of fraud with a higher degree of productivity.

  • Who is impacted?

    Infobric directly benefits individual workers with safety and task management tools. This empowers subcontractors and main contractors with better control and efficiency. Consequently, owners and developers see more transparent and compliant projects, indirectly fostering a more productive construction sector for society.

  • Contribution

    As one the most prominent players within construction tech in Northern Europe, Infobric supports the transition in the construction industry towards safety, efficiency, and sustainability.

  • Risks to impact

    Infobric manages personal data, making safeguarding data privacy and security paramount. While unlikely, the illicit use and back-solving of the software are potential scenarios for non-compliance with legislation.

Press release

Summa Equity announces the sale of its majority stake in Infobric to Stirling Square

Stockholm, 21th June 2023: Summa Equity, a purpose-driven thematic investment firm, today announces the sale of its majority stake in Infobric, a leading provider of software solutions for the European construction industry, to Stirling Square Capital Partners (“Stirling Square”) a pan-European mid-market private equity firm.

KPI reporting

Number of safety inspections made on site

Change from '23-'24: -15%

2024
33,157
2023
39,056
2022
0N/A

This measures the total count of safety inspections conducted on-site by clients, enabled by Infobric’s tools. This decrease is mainly a result of a reporting change, where finalized inspections are now counted instead of started inspections.

Number of control objects under scrutiny in Infobric Supplier Control system

Change from '23-'24: +25%

2024
250,739
2023
200,089
2022
0N/A

Number of suppliers (sub-contractors) actively monitored within the system, enabling them to reduce undocumented labor and under-payment of taxes.

Number of construction sites using­ Infobric’s Waste and Emission module

Target 2030: 50% of HMSREGs customers to utilize waste or emissions solution

Change from '23-'24: +114%

2024
92
2023
43
2022
0N/A

The number of sites utilizing the Waste and Emission module, helps assess the impact of environmentally responsible construction practices.

  1. Home
  2. Investments
  3. Vyntra

The future of transaction intelligence

Vyntra at a glance

Introducing Vyntra – created from the union of intix and NetGuardians, combining world-class expertise in financial crime prevention and transaction observability to redefine trust and transparency in financial services.

Vyntra helps financial institutions see, secure, and optimize every transaction in real time. From payment fraud and AML to transaction tracking, internal risk, and data visibility, Vyntra empowers financial institutions to detect threats faster, streamline compliance, and deliver resilient operations – without slowing down business.

Year acquired
2022
Revenue
EUR 19m
Location
Belgium
Employees
147
Investment theme
Tech-Enabled Resilience
SDG alignment

8, 10, 16

What are the challenges Vyntra addresses

  • USD 2tn

    money laundered globally
  • 14%

    increase in elder fraud complaints in 2023, indicating impact of fraud on vulnerable populations

How does Vyntra help?

  • Reality today

    Illicit financial flows undermine political and economic security around the world. Banks often utilize manual processes and/or software with low scalability to detect and hinder fraud and remain compliant, raising the costs and effort required while making it easier to make fraudulent transactions.

  • Vyntra approach

    Vyntra’s transaction monitoring tools help financial institutions view archived and indexed transaction data and monitor and track transactions to detect discrepancies and raise alerts in real time. The financial crime solutions enable financial institutions to detect and hinder fraudulent transactions and money laundering performed by criminal actors and authoritarian governments.

  • Aspirational future

    A compliant, secure, and globally accessible banking and payment structure to ensure financial stability and prosperity. One which is free from illicit financial flows, thereby hindering authoritarian governments and criminal actors to launder money and perform fraudulent transactions.

  • Who is impacted?

    Individuals and institutions directly suffer financial losses and profound emotional distress from fraud, including feelings of betrayal and lasting mental health impacts. More broadly, society endures eroded trust in institutions, increased inequality, and the funding of harmful criminal activities, ultimately impacting everyone’s safety and well-being.

  • Contribution

    Vyntra’s contributes to decreasing fraudulent transactions and money laundering directly through their fraud prevention & AML solutions as well as indirectly by enabling financial institutions to track millions of transactions daily and detect irregularities.

  • Risks to impact

    Technological efficiency risk and scaling globally.

KPI reporting

Transactions monitored

Target 2029: 20bn

Change from '23-'24: 9%

2024
10bn
2023
9bn
2022
6bn

The overall count of data points that can be viewed and analyzed using Vyntra’s Transaction Analytics Platform leading to less fraud / leading to fraudulent transactions being detected.

Fraud prevented

2024
20,350
2023
0N/A
2022
0N/A

Confirmed instances where Vyntra’s system stopped potentially fraudulent activities, reducing financial risk.

USD saved from fraud prevented

2024
352m
2023
0N/A
2022
0N/A

The calculated monetary value of losses avoided due to Vyntra’s fraud prevention capabilities.

  1. Home
  2. Investments
  3. STIM

The aquaculture industry’s largest quality supplier of fish health products and services

STIM at a glance

STIM is the aquaculture industry’s largest quality supplier of fish health products and services, with several ground-breaking innovations under its belt.

STIM strives for a holistic perspective, building on the experience from vaccines and pharmaceuticals with the expertise that lies in its broad range of services in fish health services, marine environmental surveys, support for area applications and plans, as well as regulatory advice.

After 33 years side by side with the aquaculture industry, STIM is in a unique position as a supplier of both expertise, products, and services – all the way from planning to processing. STIM is established in Norway, Chile, UK, USA, Canada, Iceland, and China.

Year acquired
2024
Revenue
NOK 175m
Location
Norway
Employees
89
Investment theme
Sustainable Food
SDG alignment

2, 14

What are the challenges Stim addresses

  • USD ~2bn

    in revenue loss for salmon farmers from mortality and downgrades
  • >15%

    fish mortality in salmon farming

How does STIM help?

  • Reality today

    Aquaculture, with its low carbon footprint and high efficiency, fits within a sustainable food system. However, it faces challenges like fish welfare and rising mortality rates, with salmon farming experiencing over 15% mortality, a figure that’s been increasing the past years.

  • STIM approach

    For over 30 years, STIM has advanced sustainable aquaculture by offering disease prevention, promoting sustainable practices, and driving innovations that enhance fish health, growth, and profitability. Their success is backed by a strong market presence and expert, cross-disciplinary teams.

  • Aspirational future

    STIM’s vision is an efficient and sustainable aquaculture industry where its main biological challenges are solved, and continued investments in fish health competence and new innovations are continuing to drive significant improvements in fish welfare and farming practices.

  • Who is impacted?

    Fish farmers benefit from good fish health and low mortality as it results in productive operations and less environmental impact.

  • Contribution

    STIM contributes to improved fish health, animal welfare, and reduced mortality through products and expertise. This leads to more sustainable and productive farming systems with reduced impact on the surrounding environment.

  • Risks to impact

    As part of the salmon farming process takes place in the ocean, farming practices or use of treatment products can have unwanted and adverse effects on the surrounding ecosystems.

KPI reporting

Increased distribution of vaccine doses

Target 2028: 42%

Change from '23-'24: +11 ppt

2024
32%
2023
21%
2022
0N/A

Year over year increase in preventative health measures by STIM AS for farmed fish.

Increased usage of SuperSmolt

Target 2028: 322%

Change from '23-'24: +50 ppt

2024
64%
2023
17%
2022
0N/A

Year over year improvement in salmon welfare by assisting in smoltification.

  1. Home
  2. Investments
  3. FAST LTA

Highly secure and compliant data storage and archiving technology solution

FAST LTA at a glance

Fast LTA is a leading German solution provider for high-security archiving, storage, and recovery of business critical and sensitive personal data. The company offers both long-term archiving and backup solutions for small to enterprise customers with requirements for robust data integrity, compliance assurance, protection against data manipulation and against ransomware.

Year acquired
2024
Revenue
EUR 27m
Location
Germany
Employees
111
Investment theme
Tech-Enabled Resilience
SDG alignment

9, 16

The challenges we face:

  • +80%

    rise in ransomware attacks in the global healthcare sector in 2023
  • 90%

    of European critical industry actors have experienced at least one cybersecurity attack in the past two years

How does FAST LTA help?


  • Reality today

    Companies in critical industries need secure data storage and recovery solutions to prevent ransomware data loss and comply with regulations. Additionally, energy-efficient storage solutions are essential to mitigate climate impact from the growing need for data processing and storage.

  • FAST LTA approach

    Fast LTA protects sensitive data for clients in sectors like healthcare and public services against ransomware, ensuring data privacy. Their solutions, including WORM technology and Air Gap, also help save energy by powering down hardware when not in use.

  • Aspirational future

    A more resilient society and infrastructure where no data is lost— and if any is, it can be recovered quickly — ensuring individuals and businesses are protected from cybercrime and can minimize recovery times after an attack.


  • Who is impacted?

    Companies in critical industries, especially healthcare, store sensitive data, benefiting individuals through increased security and reduced risk of malicious access. Business-critical information is protected and promptly restored, ensuring continuity and resilience during attacks or incidents.

  • Contribution

    FAST LTA clients in critical industries prevent data losses and business disruptions from ransomware attacks. Their replication-based disaster recovery ensures operational continuity, even if physical servers are destroyed, as seen during the 2021 Germany floods.

  • Risks to impact

    Issues resulting from human error, such as misconfiguration during setup, improper management of encryption keys, or weak access control could lead to vulnerabilities.

KPI reporting

Total customers from critical industries

Target 2027: 1,839

Change from '23-'24: 2%

2024
1,799
2023
1,767
2022
1,712

Number of clients in “critical industries” (as defined by the German Federal Office for Information Security), which are of high importance and whose failure or impairment would cause a threat to public safety or a sustained shortage of supply.

Data saved from archive product line

Target 2027: 100%

Change from '23-'24: 0ppt

2024
100%
2023
100%
2022
100%

Data protected with zero data loss demonstrates ability to safeguard sensitive data against any potential threats or failures.

Energy consumption per TB

Target 2027: 1.6

Change from '23-'24: -40%

2024
2
2023
3
2022
3

Measures the energy efficiency of FAST LTA’s storage solutions, showing watts consumed per terabyte of usable storage in a typical server room environment.